EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

AAV‐Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness

Jieyu Qi, Fangzhi Tan, Liyan Zhang, Ling Lu, Shanzhong Zhang, Yabo Zhai, Yicheng Lu, Xiaoyun Qian, WenXiu Dong, Yinyi Zhou, Ziyu Zhang, Xuehan Yang und 13 weitere

Advanced Science · 2024-03 · 11 (11)

DOI: 10.1002/advs.202306788 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Advanced Science, online erschienen am 08.01.2024. Verfasst von Jieyu Qi und 24 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Digital Medical Engineering, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences an…. Hauptthemen laut MEDLINE: Hearing Loss, Sensorineural, Deafness. Die Arbeit wurde bisher 176-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, STI2030-Major Projects, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in OTOFERLIN ( OTOF ) lead to the autosomal recessive deafness 9 (DFNB9). The efficacy of adeno‐associated virus (AAV)‐mediated OTOF gene replacement therapy is extensively validated in Otof ‐deficient mice. However, the clinical safety and efficacy of AAV‐ OTOF is not reported. Here, AAV‐ OTOF is generated using good manufacturing practice and validated its efficacy and safety in mouse and non‐human primates in order to determine the optimal injection dose, volume, and administration route for clinical trials. Subsequently, AAV‐ OTOF is delivered into one cochlea of a 5‐year‐old deaf patient and into the bilateral cochleae of an 8‐year‐old deaf patient with OTOF mutations. Obvious hearing improvement is detected by the auditory brainstem response (ABR) and the pure‐tone audiometry (PTA) in these two patients. Hearing in the injected ear of the 5‐year‐old patient can be restored to the normal range at 1 month after AAV‐ OTOF injection, while the 8‐year‐old patient can hear the conversational sounds. Most importantly, the 5‐year‐old patient can hear and recognize speech only through the AAV‐ OTOF ‐injected ear. This study is the first to demonstrate the safety and efficacy of AAV‐ OTOF in patients, expands and optimizes current OTOF ‐related gene therapy and provides valuable information for further application of gene therapies for deafness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hearing Loss, SensorineuralDeafnessHumansAnimalsMiceDependovirusHearingGenetic Therapy

Stichwörter der Autor:innen

AAVOTOF gene therapybiosafetyclinical trialhearing recovery

Autor:innen und Institutionen

  • State Key Laboratory of Digital Medical Engineering, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences and Technology, School of Medicine, Advanced Institute for Life and Heal…
  • Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, 226001, China.
  • Department of Neurology, Aerospace Center Hospital, School of Life Science, Beijing Institute of Technology, Beijing, 100081, China.
  • Department of Otolaryngology-Head and Neck Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Jiangsu Provincial Key Medical Discipline (Laboratory), Nanjing, 210008, China.
  • Otovia Therapeutics Inc, Suzhou, 215101, China.
  • School of Medicine, Southeast University, Nanjing, 210009, China.

ORCID-Profile: Renjie Chai

Förderung

  • National Key Research and Development Program of China
  • STI2030-Major Projects
  • National Natural Science Foundation of China
  • China National Postdoctoral Program for Innovative Talents
  • China Postdoctoral Science Foundation
  • Science and Technology Department of Sichuan Province
  • 2022 Open Project Fund of Guangdong Academy of Medical Sciences
  • Jiangsu Postdoctoral Research Funding Program

Zitieren

APA

Qi, J., Tan, F., Zhang, L., Lu, L., Zhang, S., Zhai, Y., Lu, Y., Qian, X., Dong, W., Zhou, Y., Zhang, Z., Yang, X., Jiang, L., Yu, C., Liu, J., Chen, T., Wu, L., Tan, C., Sun, S., …, & Chai, R. (2024). AAV‐Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness. Advanced Science, 11(11). https://doi.org/10.1002/advs.202306788

Vancouver

Qi J, Tan F, Zhang L, Lu L, Zhang S, Zhai Y, et al. AAV‐Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness. Advanced Science. 2024;11(11). doi:10.1002/advs.202306788

BibTeX
@article{Qi2024,
  author = {Qi, Jieyu and Tan, Fangzhi and Zhang, Liyan and Lu, Ling and Zhang, Shanzhong and Zhai, Yabo and Lu, Yicheng and Qian, Xiaoyun and Dong, WenXiu and Zhou, Yinyi and Zhang, Ziyu and Yang, Xuehan and Jiang, Lulu and Yu, Chaorong and Liu, Jiancheng and Chen, Tian and Wu, Lianqiu and Tan, Chang and Sun, Sijie and Song, Huaien and Shu, Yilai and Xu, Lei and Gao, Xia and Li, Huawei and Chai, Renjie},
  title = {AAV‐Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {11},
  doi = {10.1002/advs.202306788}
}
Kostenlos starten →